293 related articles for article (PubMed ID: 26935361)
1. Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis.
Bando M; Yamauchi H; Ogura T; Taniguchi H; Watanabe K; Azuma A; Homma S; Sugiyama Y;
Intern Med; 2016; 55(5):443-8. PubMed ID: 26935361
[TBL] [Abstract][Full Text] [Related]
2. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.
Harari S; Caminati A; Albera C; Vancheri C; Poletti V; Pesci A; Luppi F; Saltini C; Agostini C; Bargagli E; Sebastiani A; Sanduzzi A; Giunta V; Della Porta R; Bandelli GP; Puglisi S; Tomassetti S; Biffi A; Cerri S; Mari A; Cinetto F; Tirelli F; Farinelli G; Bocchino M; Specchia C; Confalonieri M
Respir Med; 2015 Jul; 109(7):904-13. PubMed ID: 25962649
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
Sakamoto S; Itoh T; Muramatsu Y; Satoh K; Ishida F; Sugino K; Isobe K; Homma S
Intern Med; 2013; 52(22):2495-501. PubMed ID: 24240787
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis.
Marcos Ribes B; Sancho-Chust JN; Talens A; Arlandis M; Herraiz P; Chiner E; Aznar T
Eur J Hosp Pharm; 2020 Nov; 27(6):350-354. PubMed ID: 33020058
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
Yoon HY; Kim DS; Song JW
Respiration; 2019; 97(3):242-251. PubMed ID: 30332670
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Long-term Pirfenidone Therapy in Patients with Idiopathic Pulmonary Fibrosis.
Ogawa K; Miyamoto A; Hanada S; Takahashi Y; Murase K; Mochizuki S; Uruga H; Takaya H; Morokawa N; Kishi K
Intern Med; 2018 Oct; 57(19):2813-2818. PubMed ID: 29780123
[TBL] [Abstract][Full Text] [Related]
13. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
14. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
15. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Glasscock KF; King TE; Lancaster L; Lederer DJ; Lin Z; Pereira CA; Swigris JJ; Valeyre D; Noble PW; Wells AU
Thorax; 2016 May; 71(5):429-35. PubMed ID: 26968970
[TBL] [Abstract][Full Text] [Related]
16. Pirfenidone treatment of idiopathic pulmonary fibrosis.
Azuma A
Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
[TBL] [Abstract][Full Text] [Related]
17. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
Chaudhuri N; Duck A; Frank R; Holme J; Leonard C
Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005
[TBL] [Abstract][Full Text] [Related]
18. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.
Dhooria S; Agarwal R; Sehgal IS; Prasad KT; Muth V; Garg M; Bal A; Aggarwal AN; Behera D
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):148-157. PubMed ID: 33093778
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
[TBL] [Abstract][Full Text] [Related]
20. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.
Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]